Compare Cassava Sciences Inc (FLNA) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.2. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VIG | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $239.03 |
52-Week Low | $1.09 | $204.09 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
VIG trades at $237.66 with a slight 0.15% daily gain, showing technical bullish momentum with strong moving average support. The ETF maintains focus on dividend growth stocks with consistent performance. Recent news highlights VIG as a core holding for long-term wealth building, with comparisons to peers like SCHD and DGRO emphasizing its dividend appreciation strategy.
VIG offers exposure to companies with strong dividend growth histories, positioned for steady income generation. Key risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment remains positive for dividend-focused strategies in current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
